OCUGEN, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
OCUGEN, INC. (OCGN) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 122.40 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- OCUGEN, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 58.63M shares, a 106.39% increase year-over-year.
- OCUGEN, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 28.41M shares, a 50.15% increase year-over-year.
- OCUGEN, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-09-30 was 19.64M shares, a 10.41% increase year-over-year.
- OCUGEN, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 18.92M shares, a 1.95% increase year-over-year.
- OCUGEN, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 50.23M shares, a 156.26% increase from fiscal 2024.
- OCUGEN, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 19.60M shares, a 13.17% increase from fiscal 2023.
- OCUGEN, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 17.32M shares, a 31.99% increase from fiscal 2022.
- OCUGEN, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 13.12M shares, a 12.85% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 122.40M shares 10-Q · filed 2026-08-06 | |||||||
| 2026-03-31 | 58.63M shares 10-Q · filed 2026-05-08 | |||||||
| 2025-12-31 | 50.23M shares 10-K · filed 2026-03-04 | |||||||
| 2025-09-30 | 49.63M shares 10-Q · filed 2025-11-05 | |||||||
| 2025-06-30 | 28.95M shares 10-Q · filed 2026-08-06 | |||||||
| 2025-03-31 | 28.41M shares 10-Q · filed 2026-05-08 | |||||||
| 2024-12-31 | 19.60M shares 10-K · filed 2026-03-04 | |||||||
| 2024-09-30 | 19.64M shares 10-Q · filed 2024-11-14 | 19.64M shares 10-Q · filed 2025-11-05 | ||||||
| 2024-06-30 | 19.48M shares 10-Q · filed 2025-08-04 | |||||||
| 2024-03-31 | 18.92M shares 10-Q · filed 2025-05-09 | |||||||
| 2023-12-31 | 17.32M shares 10-K · filed 2025-03-05 | |||||||
| 2023-09-30 | 17.79M shares 10-Q · filed 2024-11-14 | 17.79M shares 10-Q · filed 2024-11-14 | ||||||
| 2023-06-30 | 18.76M shares 10-Q · filed 2023-08-21 | 18.76M shares 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | 18.56M shares 10-Q · filed 2024-05-14 | |||||||
| 2022-12-31 | 13.12M shares 10-K · filed 2024-04-16 | |||||||
| 2022-09-30 | 14.01M shares 10-Q · filed 2023-11-09 | 14.01M shares 10-Q · filed 2023-11-09 | ||||||
| 2022-06-30 | 17.06M shares 10-Q · filed 2023-08-21 | 17.06M shares 10-Q · filed 2023-08-21 | ||||||
| 2022-03-31 | 18.96M shares 10-Q · filed 2023-05-05 | |||||||
| 2021-12-31 | 11.63M shares 10-K · filed 2023-02-28 | |||||||
| 2021-09-30 | 12.19M shares 10-Q · filed 2022-11-08 | 12.19M shares 10-Q · filed 2022-11-08 | ||||||
| 2021-06-30 | 11.82M shares 10-Q · filed 2022-08-05 | 11.82M shares 10-Q · filed 2022-08-05 | ||||||
| 2021-03-31 | 10.66M shares 10-Q · filed 2022-05-06 | |||||||
| 2020-12-31 | 5.09M shares 10-K · filed 2022-02-28 | |||||||
| 2020-09-30 | 5.14M shares 10-Q · filed 2021-11-09 | 5.14M shares 10-Q · filed 2021-11-09 | ||||||
| 2020-06-30 | 5.37M shares 10-Q · filed 2021-08-06 | 5.37M shares 10-Q · filed 2020-08-14 | 5.37M shares 10-Q · filed 2021-08-06 | 5.37M shares 10-Q · filed 2020-08-14 | ||||
| 2020-03-31 | 12.14M shares 10-Q · filed 2021-05-07 | 12.14M shares 10-Q · filed 2020-05-08 | ||||||
| 2019-12-31 | 10.38M shares 10-K · filed 2022-02-28 | 10.38M shares 10-K · filed 2020-03-27 | ||||||
| 2019-09-30 | 68.15M shares 10-Q · filed 2020-11-06 | 68.15M shares 10-Q · filed 2019-11-12 | 68.15M shares 10-Q · filed 2020-11-06 | 68.15M shares 10-Q · filed 2019-11-12 | ||||
| 2019-06-30 | 1.37M shares 10-Q · filed 2020-08-14 | 2.11M shares 8-K/A · filed 2019-10-07 | 1.37M shares 10-Q · filed 2020-08-14 | 2.10M shares 8-K/A · filed 2019-10-07 | ||||
| 2019-03-31 | 1.39M shares 10-Q · filed 2020-05-08 | |||||||
| 2018-12-31 | 1.50M shares 10-K · filed 2020-03-27 | |||||||
| 2018-09-30 | 1.34M shares 10-Q · filed 2019-11-12 | 1.34M shares 10-Q · filed 2019-11-12 | ||||||
| 2018-06-30 | 2.08M shares 8-K/A · filed 2019-10-07 | 2.80M shares 8-K/A · filed 2019-10-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |